What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The FDA has taken a strong stance regarding compounded GLP-1 medications, primarily due to safety and quality concerns. Here's a breakdown:

What Happened with the FDA and Compounded GLP-1s?

1. Safety and Efficacy Concerns: The FDA has not reviewed compounded GLP-1s for safety, effectiveness, or quality. They emphasize that compounded drugs do not undergo the rigorous testing and approval process that brand-name medications like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) do.
2. Incorrect Active Pharmaceutical Ingredients (APIs): A major concern has been the use of unapproved salt forms of semaglutide. The FDA has specifically warned against compounded products using semaglutide sodium or semaglutide acetate. The FDA-approved drugs use semaglutide base. The agency states that semaglutide sodium and semaglutide acetate are not the active ingredients in Ozempic or Wegovy and have not been proven safe or effective.
3. Quality and Sterility: The FDA has found issues with the quality, potency, and sterility of some compounded GLP-1 products. This can lead to serious health risks, including infections, adverse reactions, or the drug simply not working as intended.
4. Misleading Marketing: Many compounding pharmacies and online clinics were advertising and selling compounded semaglutide as if it were identical to the FDA-approved versions, often at lower prices, which caught the FDA's attention.
5. Shortage-Driven Compounding: Under federal law, compounding pharmacies can generally only compound a drug that is essentially a copy of an FDA-approved drug if the approved drug is on the FDA's drug shortage list. Due to the high demand, Ozempic and Wegovy have been on this list at various times, which allowed some limited, legitimate compounding under specific conditions. However, the FDA asserts that even during a shortage, pharmacies must use pharmaceutical-grade ingredients and adhere to strict compounding regulations.

Who is Still Operating Legally (and How)?

It's crucial to understand the difference between legal, regulated compounding and unregulated, potentially dangerous practices.

Legitimate avenues for obtaining GLP-1s are primarily through FDA-approved medications:

1. FDA-Approved Brand Name Medications:
   • Ozempic (semaglutide, for type 2 diabetes, often used off-label for weight loss)
   • Wegovy (semaglutide, specifically approved for chronic weight management)
   • Mounjaro (tirzepatide, for type 2 diabetes, often used off-label for weight loss)
   • Zepbound (tirzepatide, specifically approved for chronic weight management) These are prescribed by a licensed healthcare provider and dispensed by a licensed pharmacy, adhering to all FDA standards. This is the safest and most recommended route.

For compounded GLP-1s, legal operation is highly restricted and subject to strict rules:

Compounding pharmacies operate under one of two classifications:

1. 503A Compounding Pharmacies:

   • These are traditional, state-licensed pharmacies that prepare individualized medications for specific patients based on a valid prescription.
   • They are generally allowed to compound a drug that is a copy of an FDA-approved drug only when that approved drug is on the FDA's drug shortage list AND there is a patient-specific medical need.
   • They must use pharmaceutical-grade ingredients (APIs).
   • Crucially, they must use the correct active pharmaceutical ingredient. For semaglutide, this means pharmaceutical-grade semaglutide base, not semaglutide sodium or semaglutide acetate.
   • They are subject to state board of pharmacy oversight.

2. 503B Outsourcing Facilities:

   • These facilities voluntarily register with the FDA and are subject to FDA inspections and current Good Manufacturing Practice (cGMP) standards, similar to drug manufacturers.
   • They can produce larger batches of compounded sterile drugs for hospitals and healthcare providers without individual patient prescriptions in advance.
   • Like 503A pharmacies, they are generally not allowed to compound "essentially copies" of FDA-approved drugs unless those drugs are on the FDA's drug shortage list.
   • They must also use the correct, pharmaceutical-grade API (e.g., semaglutide base).
   • They are subject to federal (FDA) oversight.

Who is not operating legally (according to the FDA):

• Any entity selling compounded semaglutide using semaglutide sodium or semaglutide acetate.
• Compounding pharmacies or clinics that are mass-producing or widely advertising compounded GLP-1s when the FDA-approved version is not on the drug shortage list, or when they are not adhering to patient-specific prescription requirements.
• Pharmacies or online services that cannot provide transparent information about their active pharmaceutical ingredient source, quality control, or facility registration.

If you are considering a compounded GLP-1, it is essential to:

• Consult a licensed healthcare provider.
• Ask direct questions of the pharmacy: What is the source of the active ingredient? Which salt form of semaglutide are they using (should be semaglutide base)? Are they a 503A or 503B facility? How do they ensure quality and sterility?
• Be wary of unusually low prices or clinics promising quick, easy access without proper medical evaluation.

The safest and most legitimate way to access GLP-1 medications is always through FDA-approved brands like Ozempic, Wegovy, Mounjaro, or Zepbound, prescribed by a qualified medical professional.